Predictors of cancer-specific mortality after disease recurrence following radical cystectomy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F13%3A10209770" target="_blank" >RIV/00216208:11130/13:10209770 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/13:10209770

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1464-410X.2012.11433.x" target="_blank" >http://dx.doi.org/10.1111/j.1464-410X.2012.11433.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1464-410X.2012.11433.x" target="_blank" >10.1111/j.1464-410X.2012.11433.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Predictors of cancer-specific mortality after disease recurrence following radical cystectomy

Popis výsledku v původním jazyce

Study Type Therapy (case series) Level of Evidence4 What's known on the subject? and What does the study add? Outcomes after disease recurrence in patients with urothelial carcinoma of the bladder treated with radical cystectomy are variable, but the majority of patients die from the disease within 2 years after disease recurrence. Knowledge about prognostic factors that may influence survival after disease recurrence is limited. We found that outcomes after disease recurrence in patients with urothelial carcinoma of the bladder are significantly affected by common clinicopathological factors. In addition, a shorter time from surgery to disease recurrence is significantly associated with poor outcomes. These factors should be considered when schedulingsalvage chemotherapy protocols/clinical trials.

Název v anglickém jazyce

Predictors of cancer-specific mortality after disease recurrence following radical cystectomy

Popis výsledku anglicky

Study Type Therapy (case series) Level of Evidence4 What's known on the subject? and What does the study add? Outcomes after disease recurrence in patients with urothelial carcinoma of the bladder treated with radical cystectomy are variable, but the majority of patients die from the disease within 2 years after disease recurrence. Knowledge about prognostic factors that may influence survival after disease recurrence is limited. We found that outcomes after disease recurrence in patients with urothelial carcinoma of the bladder are significantly affected by common clinicopathological factors. In addition, a shorter time from surgery to disease recurrence is significantly associated with poor outcomes. These factors should be considered when schedulingsalvage chemotherapy protocols/clinical trials.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BJU International

ISSN

1464-4096

e-ISSN

—

Svazek periodika

111

Číslo periodika v rámci svazku

3B

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

"E30"-"E36"

Kód UT WoS článku

000315642700002

EID výsledku v databázi Scopus

—